Drug Channels

AUGUST 31, 2021

Charlotte Morabito at CNBC has put together “Why Pharmacies Overcharge,” an entertaining and provocative video on the pharmacy industry and its generic prescription pricing. It’s definitely worth your time. I especially enjoyed the cool visualizations of Drug Channels Institute’s industry data. Links below. The video covers the history of pharmacy, from the “Soda Fountain Era” to “Lick, Stick, and Pour” to the rise of PBMs and GoodRx. .

Pharmacy 97

Pharmacy Drugs 97

Drug Patent Watch

AUGUST 30, 2021

Annual Drug Patent Expirations for NAPROXEN+SODIUM Naproxen Sodium is a drug marketed by Bionpharma Inc, Catalent, Puracap Pharm Llc, Actavis Labs Fl Inc, Able, Amneal Pharms Ny, Aurobindo Pharma Ltd,…. The post New patent for Bionpharma Inc drug NAPROXEN SODIUM appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 88

Drugs Marketing 88

The Pharma Data

SEPTEMBER 2, 2021

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a distant organ is promoted by factors whose production is induced by the primary tumor itself. Scientists from the German Cancer Research Center (DKFZ) and the Medical Faculty Mannheim, Heidelberg University, have now identified a new growth factor produced by blood vessels that enables tumor cells to metastatically colonize organs.

Research 52

Research Regulations Science Production 52

Crown Bioscience

SEPTEMBER 1, 2021

In this post we explore the different in vitro potency assays for assessing the function of anti-PD-1 checkpoint inhibitors, which are used to test the T cell response of anti-PD-1 (programmed death-1) agents.

52

52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Practical Cheminformatics

AUGUST 31, 2021

A pointer to the fastpages site.

40

40

Drug Patent Watch

SEPTEMBER 3, 2021

Annual Drug Patent Expirations for QUILLICHEW+ER Quillichew Er is a drug marketed by Nextwave Pharms and is included in one NDA. It is available from two suppliers. There are seven…. The post New patent for Nextwave Pharms drug QUILLICHEW ER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The ChEMBL-og

SEPTEMBER 1, 2021

Infectious disease is a leading cause of death globally and bioactivity data against pathogens (fungi, bacteria, viruses, and parasites) is an important category in ChEMBL, especially in light of the ongoing pandemic. In ChEMBL version 29, there are over 2 M bioactivity data points against fungal, bacterial or viral targets (for 460 K compounds) available for pathogen-related research.

Cell Based Assays 52

Cell Based Assays Screening Hits Small Molecule Virus 52

Drug Patent Watch

SEPTEMBER 3, 2021

Annual Drug Patent Expirations for MINOLIRA Minolira is a drug marketed by Epi Hlth and is included in one NDA. The generic ingredient in MINOLIRA is minocycline hydrochloride. Additional details…. The post New patent for Epi Hlth drug MINOLIRA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 2, 2021

Annual Drug Patent Expirations for CLEVIPREX Cleviprex is a drug marketed by Chiesi and is included in one NDA. It is available from two suppliers. There are three patents protecting…. The post New patent for Chiesi drug CLEVIPREX appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 2, 2021

Annual Drug Patent Expirations for OLINVYK Olinvyk is a drug marketed by Trevena and is included in one NDA. There are three patents protecting this drug. This drug has thirty-five…. The post New patent for Trevena drug OLINVYK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

The Pharma Data

SEPTEMBER 1, 2021

INVEGA HAFYERA™ offers patients the fewest doses per year for a life less defined by schizophrenia medication. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months. Approval is backed by nearly two decades of proven efficacy and safety of Janssen’s long-acting injectable portfolio of schizophrenia medicines.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

The Pharma Data

SEPTEMBER 1, 2021

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: Morgan Stanley Annual Global Healthcare Conference on Wednesday, September 15 at 12:30pm ET. The live webcast can be accessed at the company’s investors page at investors.gilead.com. The replay will be available for at least 30 days following the presentation.

Science 52

Science Disease 52

The Pharma Data

SEPTEMBER 1, 2021

Cambridge, MA.— Biogen Inc. (Nasdaq: BIIB) announced today that it will participate in a live Q&A at the Morgan Stanley 19th Annual Global Healthcare Conference. The webcast will be live on Thursday, September 9, at 9:30 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at investors.biogen.com. An archived version of the webcast will be available following the presentation.

Biosimilars 52

Biosimilars Disease Therapies Treatment 52

The Pharma Data

SEPTEMBER 1, 2021

Study Now Enrolling Participants Who Live in the Same Household as Someone With Symptomatic, Laboratory-Confirmed COVID-19. Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the initiation of the Phase 3 MOVe-AHEAD clinical trial to evaluate molnupiravir, an investigational oral antiviral therapeutic, for the prevention of COVID-19 infection.

Laboratories 52

Laboratories Virus Clinical Trials Research Laboratories 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

The Pharma Data

SEPTEMBER 1, 2021

Great Place to Work® and PEOPLE magazine have honored AbbVie as one of the 2021 PEOPLE Companies that Care ®. This is AbbVie’s third consecutive time being named to this list. Published by PEOPLE, the Companies that Care list highlights the top US companies that have succeeded in business while also demonstrating outstanding respect, care and concern for their employees, their communities and the environment.

Vaccine 52

Vaccine 52

The Pharma Data

SEPTEMBER 2, 2021

(“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS). The trial evaluated whether the combination of pevonedistat plus azacitidine as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low-blast acute myeloid leukemia (AML) improved EFS versus azacitidine alone.

Trials 52

Trials Therapies Treatment Science 52

Drug Patent Watch

SEPTEMBER 1, 2021

Annual Drug Patent Expirations for BELRAPZO Belrapzo is a drug marketed by Eagle Pharms and is included in one NDA. It is available from one supplier. There are six patents…. The post New patent for Eagle Pharms drug BELRAPZO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 1, 2021

Annual Drug Patent Expirations for COMETRIQ Cometriq is a drug marketed by Exelixis and is included in one NDA. It is available from one supplier. There are three patents protecting…. The post New patent for Exelixis drug COMETRIQ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 1, 2021

Annual Drug Patent Expirations for BENDEKA Bendeka is a drug marketed by Eagle Pharms and is included in one NDA. It is available from one supplier. There are fifteen patents…. The post New patent for Eagle Pharms drug BENDEKA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 1, 2021

Annual Drug Patent Expirations for CABOMETYX Cabometyx is a drug marketed by Exelixis Inc and is included in one NDA. It is available from one supplier. There are six patents…. The post New patent for Exelixis Inc drug CABOMETYX appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

AUGUST 31, 2021

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim Phase 1/2 results. The randomised, active-controlled global trial will enrol around 4,000 participants from a range of countries and will aim to evaluate GBP510’s safety and immunogenicity compared to an active comparator – the AstraZeneca/Oxford Univer

Trials 52

Trials Vaccine Clinical Trials Treatment 52

The Pharma Data

AUGUST 31, 2021

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia has been accepted by the U.S. Food and Drug Administration (FDA).

FDA 52

FDA Treatment Drugs Hospitals 52

The Pharma Data

AUGUST 31, 2021

Eli Lilly and Company (NYSE: LLY) will participate in Citi’s 16th Annual BioPharma Virtual Conference on September 8 and 9, 2021. Anat Ashkenazi, senior vice president and chief financial officer, will participate in a virtual fireside chat on Thursday, September 9 at 9:45 a.m., Eastern Time. A live audio webcast will be available on the “Webcasts & Presentations” section of Lilly’s Investor website at [link].

52

52

The Pharma Data

AUGUST 31, 2021

today announced a label update for KEYTRUDA, Merck’s anti-PD-1 therapy, for its indication in first-line advanced urothelial carcinoma (bladder cancer) in the U.S. The U.S. Food and Drug Administration (FDA) has converted this indication from an accelerated to a full (regular) approval. In addition, as part of the label update, this indication has been revised to be for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for any platinum-

FDA Approval 52

FDA Approval Treatment FDA Research Laboratories 52

The Pharma Data

AUGUST 31, 2021

Compelled to advance innovation for patients and the urology community, oral presentations highlight real-world effectiveness of and patient adherence to ERLEADA ® (apalutamide), plus PSA response from Phase 3 TITAN and SPARTAN studies in patients with advanced prostate cancer. The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Associati

Treatment 52

Treatment Trials FDA Approval Pharmaceutical Companies 52

Drug Patent Watch

AUGUST 31, 2021

Annual Drug Patent Expirations for BALVERSA Balversa is a drug marketed by Janssen Biotech and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for Janssen Biotech drug BALVERSA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

AUGUST 30, 2021

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published today in the Journal of the American College of Cardiology (JACC). The most severe form of COVID-19 is severe respiratory failure, which requires intubation and is associated with a high mortality rate.

Clinical Trials 52

Clinical Trials Drugs Trials Hospitals 52

The Pharma Data

AUGUST 30, 2021

Separate post hoc analyses of pooled Phase III ORION-9, -10 and -11 data show twice-yearly** Leqvio ® (inclisiran) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD) with established cerebrovascular disease (CeVD) 1 and polyvascular disease (PVD) 2. Overall, Leqvio was well-tolerated, with a safety profile similar to placebo and consistent with the overall pooled population from the combined trials 1 – 3.

RNA 52

RNA Disease Trials Therapies 52

The Pharma Data

AUGUST 30, 2021

-JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies-. today announced that JADE DARE (B7451050), a 26-week, randomized, double-blind, double-dummy, active-controlled, multi-center Phase 3 study, met its co-primary and key secondary efficacy endpoints. The study showed that abrocitinib was statistically superior compared to dupilumab in each evaluated efficacy measure and had a safety profile consistent with previous studi

Small Molecule 52

Small Molecule Trials Treatment FDA 52

Drug Patent Watch

AUGUST 30, 2021

Annual Drug Patent Expirations for INCIVEK Incivek is a drug marketed by Vertex Pharms and is included in one NDA. There are three patents protecting this drug. This drug has…. The post New patent expiration for Vertex Pharms drug INCIVEK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

AUGUST 30, 2021

Annual Drug Patent Expirations for XIFAXAN Xifaxan is a drug marketed by Salix Pharms and is included in two NDAs. It is available from three suppliers. There are twenty-seven patents…. The post New patent for Salix Pharms drug XIFAXAN appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

AUGUST 30, 2021

today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1, as determined by a US Food and Drug Administration (FDA)-approved test.

FDA 52

FDA Treatment Therapies FDA Approval 52

The Pharma Data

AUGUST 30, 2021

FIGARO-DKD detailed study results confirmed the cardiovascular benefits of finerenone as demonstrated in the FIDELIO-DKD study, focusing on chronic kidney disease (CKD) and type 2 diabetes (T2D) across a broad range of disease severity, including patients with stages 1-4 CKD and T2D / Results from the FIGARO-DKD study were simultaneously published in the New England Journal of Medicine / Results from FIDELITY, a prespecified meta-analysis of more than 13,000 patients from the Phase III studies F

Hospitals 52

Hospitals Disease Clinical Trials Therapies 52

The Pharma Data

AUGUST 30, 2021

ALXN1840 demonstrated approximately three times greater copper mobilisation from tissues than standard-of-care treatments. Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments.

Disease 52

Disease Trials Therapies Treatment 52